# IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market
Canonical URL: https://biopharmsignal.com/news/ICCM/icecure-showcases-prosenser-cryoablation-at-american-society-of-breast-surgeons-2026-annual-meeting-as-commercial-momentum-accelerates-in-the-u-s-market
Ticker: ICCM
Company: IceCure Medical
Source: IceCure Medical
Published: 2026-05-05 12:30 EST
Original Source URL: https://ir.icecure-medical.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-14 12:32 EST — [IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation](https://biopharmsignal.com/news/ICCM/icecure-expands-u-s-commercial-team-to-meet-surging-demand-for-prosense-cryoabla-7980c317) — Source: IceCure Medical
- 2026-07-06 12:11 EST — [IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer](https://biopharmsignal.com/news/ICCM/icecure-highlights-expanding-commercial-adoption-of-prosense-cryoablation-in-bra-814ddba1) — Source: IceCure Medical
- 2026-06-25 12:12 EST — [IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement](https://biopharmsignal.com/news/ICCM/icecure-regains-compliance-with-nasdaq-minimum-bid-price-requirement-7340e049) — Source: IceCure Medical
- 2026-06-23 12:10 EST — [IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer](https://biopharmsignal.com/news/ICCM/icecure-highlights-new-peer-reviewed-journal-article-in-leading-surgery-journal--2af39cdd) — Source: IceCure Medical
- 2026-06-17 17:14 EST — [IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor](https://biopharmsignal.com/news/ICCM/icecure-announces-pricing-of-5-5-million-private-placement-priced-at-a-premium-t-b922b2c5) — Source: IceCure Medical
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)